Acetyl Hexapeptide-3 (Argireline) vs Leuphasyl
SNARE complex inhibitor that reduces expression wrinkles through topical neuromuscular modulation — the 'Botox in a bottle' peptide.
Enkephalin-mimetic cosmetic peptide that reduces expression wrinkles by modulating acetylcholine release at the neuromuscular junction, offering a Botox-like topical alternative.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Acetyl Hexapeptide-3 (Argireline)
5–10 %
Leuphasyl
5–5 %
Frequency
Acetyl Hexapeptide-3 (Argireline)
Once daily
Leuphasyl
Once daily
Administration
Acetyl Hexapeptide-3 (Argireline)
Topical
Leuphasyl
Topical application (serums, creams, ampoules)
Cycle length
Acetyl Hexapeptide-3 (Argireline)
Ongoing/indefinite
Leuphasyl
Ongoing/indefinite
Onset speed
Acetyl Hexapeptide-3 (Argireline)
Moderate (1-2 weeks)
Leuphasyl
Slow (5+ weeks)
Evidence level
Acetyl Hexapeptide-3 (Argireline)
Limited human trials
Leuphasyl
Moderate human trials (Phase 1-2)
Benefit ratings
Expression Wrinkle Reduction
Non-Invasive Treatment
Safety Profile
Wrinkle Reduction
Skin Smoothing
Anti-Aging Prevention
Compound specifications
Acetyl Hexapeptide-3 (Argireline)
Molecular formula
C35H62N14O11S
Molecular weight
887.0 Da
Half-life
Topical stability dependent on formulation; methionine residue susceptible to oxidation; stable at pH 5.5-7.7
Bioavailability
Limited skin penetration (0.22-0.54%); primarily acts at stratum corneum and superficial epidermis; O/W emulsions enhance delivery
CAS number
616204-22-9
Leuphasyl
Molecular formula
C29H39N5O7
Molecular weight
569.65 g/mol
Half-life
Topical application (local activity, systemic half-life not applicable)
Bioavailability
Limited (topical peptide; skin penetration challenged by hydrophilic nature and molecular size)
CAS number
64963-01-5
Dosing compared
Acetyl Hexapeptide-3 (Argireline)
Topical
5-10% concentration (cream or serum)
Twice daily (morning and evening) · Minimum 28-30 days; ongoing use to maintain effect
Used as a leave-on skin cream or serum. In studies, a 10% formula applied twice a day around the eyes reduced wrinkle depth by about 17% after 15 days and up to 27-30% after 30 days. It works on the skin surface only and is not injected. [1][2]
Leuphasyl
Topical
2% Leuphasyl in formulation
Once or twice daily · 4-8 weeks
Lowest concentration shown to give significant wrinkle reduction in cosmetic testing; 2% was the threshold at which measurable improvement appeared over ~2 months of daily use [6].
5% Leuphasyl in formulation
Once or twice daily · At least 4 weeks
Manufacturer in-vivo concentration; 5% Leuphasyl reduced wrinkles ~11% after 28 days, and ~25% (up to 47%) when paired with 5% Argireline [6].
Best suited for
Acetyl Hexapeptide-3 (Argireline)
Individuals seeking non-invasive reduction of expression lines and dynamic wrinkles
Acetyl Hexapeptide-3 (Argireline) is particularly well-suited for individuals focused on individuals seeking non-invasive reduction of expression lines and dynamic wrinkles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those with needle phobia who want botulinum toxin-like effects without injections
Acetyl Hexapeptide-3 (Argireline) is particularly well-suited for individuals focused on those with needle phobia who want botulinum toxin-like effects without injections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
People targeting crow's feet, forehead lines, and glabellar creases
Acetyl Hexapeptide-3 (Argireline) is particularly well-suited for individuals focused on people targeting crow's feet, forehead lines, and glabellar creases. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Individuals looking for preventive anti-wrinkle treatment to slow expression line formation
Acetyl Hexapeptide-3 (Argireline) is particularly well-suited for individuals focused on individuals looking for preventive anti-wrinkle treatment to slow expression line formation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Leuphasyl
Expression line reduction
Leuphasyl is particularly well-suited for individuals focused on expression line reduction. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Fine line prevention
Leuphasyl is particularly well-suited for individuals focused on fine line prevention. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Age management
Leuphasyl is particularly well-suited for individuals focused on age management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Non-invasive wrinkle reduction
Leuphasyl is particularly well-suited for individuals focused on non-invasive wrinkle reduction. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Side effects
Acetyl Hexapeptide-3 (Argireline)
Common
- Mild Skin Irritation
- Transient Redness
- Slight Dryness
- Stinging on Compromised Skin
Uncommon
- Contact Dermatitis
Serious
- Allergic Contact Dermatitis
Leuphasyl
Common
- Mild discomfort at treatment site
- Mild skin tingling
- Mild redness at application site
Uncommon
- Temporary skin dryness
Serious
- Severe allergic reaction
Safety & evidence
Acetyl Hexapeptide-3 (Argireline)
Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Acetyl Hexapeptide-3 demonstrates an excellent safety profile for topical cosmetic use with no serious adverse events reported in clinical studies. At the 10% concentrations used in cosmetic formulations, systemic absorption is minimal and no neurotoxicity has been observed despite its mechanism of action on the neuromuscular junction. The peptide shows a safety margin of approximately 100-fold compared to toxic reference compounds. Primary concerns are limited to local skin irritation in sensitive individuals, such as mild erythema, transient stinging, or contact dermatitis in those with peptide hypersensitivity.
Contraindications
- Known hypersensitivity to acetyl hexapeptide-3 or formulation components
- Active skin infections or open wounds at the application site
- No known systemic contraindications at cosmetic concentrations
- Use with caution in individuals with neuromuscular disorders (theoretical concern)
Leuphasyl
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Leuphasyl (Pentapeptide-18) has been studied in cosmetic research for over 15 years. This topical enkephalin-mimetic peptide demonstrates an excellent safety profile in cosmetic formulations, with no reported serious adverse effects in clinical applications. As a topical cosmetic ingredient, it avoids systemic absorption concerns associated with injectable treatments. The peptide is well-tolerated across all skin types including sensitive skin. Individual responses can vary with formulation and concentration, but most effects are manageable with standard cosmetic application protocols.
Contraindications
- Known hypersensitivity to peptides
- Open wounds or broken skin at application site
- Active dermatological infections at application site
Which is right for you?
Choose Acetyl Hexapeptide-3 (Argireline) if...
- Individuals seeking non-invasive reduction of expression lines and dynamic wrinkles
- Those with needle phobia who want botulinum toxin-like effects without injections
- People targeting crow's feet, forehead lines, and glabellar creases
- Individuals looking for preventive anti-wrinkle treatment to slow expression line formation
Choose Leuphasyl if...
- Expression line reduction
- Fine line prevention
- Age management
- Non-invasive wrinkle reduction